HOME >> BIOLOGY >> NEWS
Completion of the Drosophila genome sequence

The Drosophila research community thanks Celera Genomics and the publicly-funded genome projects for delivering the fruitfly genome sequence

PITTSBURGH, PENN. March 23, 2000 -- The publication and release of the complete DNA sequence of the fruit fly Drosophila in the current issue of Science reports an achievement that will have enormous impact on understanding human biology and disease. Nearly two-thirds of the genes known to cause human disease are present in the Drosophila genome, including genes responsible for birth defects, neurodegeneration, and cancer. These findings demonstrate that basic research using Drosophila has enormous value in the fight against human disease.

This occasion caps a century of ground-breaking discoveries made using Drosophila, several of which were recognized by Nobel prizes. These include the demonstration that radiation causes mutations and the discovery of genes that control the basic body plan of all organisms.

Drosophila has the largest genome sequence produced to date. This daunting project was only accomplished at an accelerated pace because private industry and government funded public efforts collaborated in a true partnership. The Drosophila Board, representing the community of Drosophila researchers, sincerely thanks Celera Genomics, Inc. and the Drosophila Genome Projects for providing this important resource to our research community.

The completion of the Drosophila genome sequence heralds a new era of biomedical discovery. The Drosophila community welcomes this leap forward and the opportunity it affords to advance our understanding of how organisms function and how genetic defects cause disease.

The Drosophila Genome Project is a consortium of the Berkeley Genome Project, European Genome Project, Baylor College of Medicine Human Genome Center, and FlyBase. The Dros
'"/>

Contact: Gary Karpen
karpen@salk.edu
412-281-3700 ext2606
Salk Institute
22-Mar-2000


Page: 1 2

Related biology news :

1. A room with a view for the International Space Station: Completion of the cupola observation module
2. Completion of comprehensive index of human proteins to be presented at New York Academy Of Sciences
3. Drosophila genome sequence completed
4. Scientists sequence genome of kind of organism central to biospheres carbon cycle
5. Keep genome data freely accessible
6. The book opens on the first tree genome
7. NSF awards 22 new projects for plant genome research
8. Milk genome symposium
9. Environmental decontamination, greenhouse gases, and the genome of a methane-loving bacterium
10. Scientists explore genome of methane-breathing microbe
11. National Academies advisory: genome data and bioterrorism

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Completion the genome sequence

(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... , ... July 30, 2015 , ... As part of its 2015 growth plan and ... and technical service business units, Whitehouse Laboratories is pleased to announce that it ... to the Container Center of Excellence and will be strictly dedicated to basic USP 51, ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional performance in ... , as well as solid contributions from Korea, India ... Middle East / Africa (Q2 2015: ... , Turkey and the United Kingdom ... excluding U.S. HPV sales, on demand across all customer classes. The top seven ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
Cached News: